A series of cardiometabolic-related news items have been observed from Lilly, Inventiva, Sagimet Biosciences, Abbott, and NeuroBo Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.
Five cardiometabolic-related news items have been observed from Novo Nordisk, NeuroBo, Merck, Roche, and Sanofi. Below, FENIX provides the highlights and insights for the respective news items.
During the holiday break, a series of cardiometabolic-related news items were observed from Zealand, Cytokinetics, NeuroBo, Insulet, Royal North Shore Hospital, Novo Nordisk, and Glucotrack. Below, FENIX provides highlights and insights for the respective news items.
Four cardiometabolic-related news items have been observed: Novo Nordisk has reportedly hired PCI Pharma Services to handle Wegovy pen assembly (view article); Roche announced it has obtained 510(k) clearance from FDA for its Accu-Chek Solo micropump system for individuals aged 2 years and older with T1DM (view press release); Beta Bionics posted a video on LinkedIn introducing the iLet Bionic Pancreas in a webinar titled, “Introduction to the iLet Webinar” (view LinkedIn post); and NeuroBo Pharmaceuticals announced the dosing of the first patient in its Ph2a trial evaluating DA-1241, a novel G-protein-coupled receptor 119 (GPR119) agonist for the treatment of NASH (view press release). Below, FENIX provides highlights and insights into the respective news items.
Four cardiometabolic-related news items have been observed: Alnylam (press release; slides) and Regeneron (press release; slides) hosted their respective Q2 ’23 earning calls; Ionis announced it entered a collaboration and license agreement with Novartis for the discovery, development, and commercialization of a medicine for patients with Lp(a)-driven CVD (view press release); and NeuroBo Pharmaceuticals announced it received IRB approval for its first site to proceed with the Ph2a clinical trial of DA-1241 (GPR119 agonist) for the treatment of NASH (view press release). Below, FENIX provides highlights and insights for the respective news items.
Three cardiometabolic-related news items have been observed: D&D Pharmatech announced positive topline results from its Ph1 SAD/MAD trial of DD01, a long-lasting dual GLP-1/glucagon receptor agonist, in overweight/obese patients with T2DM and NAFLD (view press release; CT.gov record); NeuroBo Pharmaceuticals announced FDA has cleared its IND application for DA-1241, a novel G-protein-coupled receptor 119 (GPR119) agonist (view press release); and Pfizer hosted its Q1 ’23 earnings call (view press release; slides) and provided a few GLP-1RA comments during Q&A. Below, FENIX provides highlights and insights into the respective news items.